The analysis discusses Novo Nordisk (NVO) stock, currently trading around $46 per share, significantly down from its 52-week high of $112. The analysis mentions that Novo Nordisk reported double-digit sales and profit growth but still cut guidance, warning of slower growth, tougher competition, and pricing pressure. Despite this, analysts maintain a moderate buy rating with a potential 52% upside. The analysis highlights that Novo's international sales jumped 26% in the APAC region, which could offset the US slowdown affecting sentiment. Because the company is growing faster overseas, the analyst believes the story may not be over.